PMID- 37240509
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230530
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 10
DP  - 2023 May 11
TI  - Consensus Statements from the Diabetologists & Endocrinologists Alliance for the 
      Management of People with Hypertension and Type 2 Diabetes Mellitus.
LID - 10.3390/jcm12103403 [doi]
LID - 3403
AB  - Hypertension and type 2 diabetes mellitus (T2DM) are important, intertwined 
      public health issues. People with both conditions face significantly elevated 
      risks of cardiovascular (CV) and renal complications. To optimize patient care, a 
      multidisciplinary expert panel met to review recent evidence on optimal blood 
      pressure (BP) targets, implications of albuminuria, and treatment regimens for 
      hypertensive patients with T2DM, with the aim of providing recommendations for 
      physicians in Hong Kong. The panel reviewed the relevant literature, obtained by 
      searching PubMed for the publication period from January 2015 to June 2021, to 
      address five discussion areas: (i) BP targets based on CV/renal benefits; (ii) 
      management of isolated systolic or diastolic hypertension; (iii) roles of 
      angiotensin II receptor blockers; (iv) implications of albuminuria for CV/renal 
      events and treatment choices; and (v) roles and tools of screening for 
      microalbuminuria. The panel held three virtual meetings using a modified Delphi 
      method to address the discussion areas. After each meeting, consensus statements 
      were derived and anonymously voted on by every panelist. A total of 17 consensus 
      statements were formulated based on recent evidence and expert insights regarding 
      cardioprotection and renoprotection for hypertensive patients with T2DM.
FAU - Tong, Peter Chun-Yip
AU  - Tong PC
AD  - Diabetologists & Endocrinologists Alliance, Hong Kong SAR, China.
FAU - Chan, Susanna Chi-Pun
AU  - Chan SC
AD  - Diabetologists & Endocrinologists Alliance, Hong Kong SAR, China.
FAU - Chan, Wing-Bun
AU  - Chan WB
AD  - Diabetologists & Endocrinologists Alliance, Hong Kong SAR, China.
FAU - Ho, Kelvin Kai-Leung
AU  - Ho KK
AD  - Diabetologists & Endocrinologists Alliance, Hong Kong SAR, China.
FAU - Leung, Godwin Tat-Chi
AU  - Leung GT
AD  - Diabetologists & Endocrinologists Alliance, Hong Kong SAR, China.
FAU - Lo, Stanley Hok-King
AU  - Lo SH
AD  - Diabetologists & Endocrinologists Alliance, Hong Kong SAR, China.
FAU - Mak, Gary Yiu-Kwong
AU  - Mak GY
AD  - Diabetologists & Endocrinologists Alliance, Hong Kong SAR, China.
FAU - Tse, Tak-Sun
AU  - Tse TS
AD  - Diabetologists & Endocrinologists Alliance, Hong Kong SAR, China.
LA  - eng
GR  - not applicable/Diabetologists & Endocrinologists Alliance/
PT  - Journal Article
PT  - Review
DEP - 20230511
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10219181
OTO - NOTNLM
OT  - albuminuria
OT  - angiotensin receptor blockers
OT  - hypertension
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict to interest.
EDAT- 2023/05/27 09:42
MHDA- 2023/05/27 09:43
PMCR- 2023/05/11
CRDT- 2023/05/27 01:17
PHST- 2023/03/17 00:00 [received]
PHST- 2023/05/04 00:00 [revised]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2023/05/27 09:43 [medline]
PHST- 2023/05/27 09:42 [pubmed]
PHST- 2023/05/27 01:17 [entrez]
PHST- 2023/05/11 00:00 [pmc-release]
AID - jcm12103403 [pii]
AID - jcm-12-03403 [pii]
AID - 10.3390/jcm12103403 [doi]
PST - epublish
SO  - J Clin Med. 2023 May 11;12(10):3403. doi: 10.3390/jcm12103403.